Journal: International journal of molecular sciences

Article Title: Surgical Site-Released Tissue Is Potent to Generate Bone onto TCP and PCL-TCP Scaffolds In Vitro.

doi: 10.3390/ijms242115877

Figure Lengend Snippet: Figure 6. (a–c) ELISA boxplots of the osteogenic markers osteocalcin (a), osteopontin (b), and collagen I (c). Boxplots compare the concentration of ocn, opn, and col I in the control group with the PCL-TCP and β-TCP group over the cultivation time of 6 weeks. Groups are further subdivided into the condition’s agarose and glue, to examine if the chosen adhesive, used for the attachment of the scaffolds onto the plastic wells, makes a difference in protein expression. The boxblots indicating the median within the 25–75% percentile. The dots represent single outliners during measurements.

Article Snippet: Enzyme-linked immunosorbent assays (ELISAs) (human Duoset ELISA kit, R&D Systems, Bio Techne, Minneapolis, MN, USA) were then performed using the supernatants at a dilution of 1:10 for osteocalcin (1:50; pure for collagen and pure for osteopontin) according to the manufacturer’s protocol and measured at 450 nm using a Multiscan Ascent reader (Thermo Scientific).

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Control, Adhesive, Expressing

Journal: Cancer science

Article Title: Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.

doi: 10.1111/j.1349-7006.2009.01159.x

Figure Lengend Snippet: Fig. 7. Triptolide potently abrogates the growth of cells and decreases KIT expression in xenografts of human mast cells carrying D816V KIT. BALB/c nu/nu nude mice bearing s.c.- innoculated HMC-1.2 xenografts were randomized into two groups (10 animals each) for treatment with DMSO containing medium (control) or triptolide 0.15 mg/kg/day. The tumor growth curves are plotted (a). The vertical axis represents the tumor size, and the horizontal axis represents the number of days since triptolide treatment began. Error bars, SE. Images for one representative mouse from each group are shown (b). On day 21, tumor xenografts in mice were dissected and measured. The bar chart (c) shows the weight of the tumors from each group (n = 10). Error bars, SE. *P < 0.0001 by Student’s t-test. (d) The expression of KIT was greatly inhibited by triptolide. Immnunohistochemical analysis with anti-CD117 antibody (KIT) and H&E in xenograft tissues from mice on day 21 after triptolide treatment.

Article Snippet: Antibodies and their sources were as follows: rabbit polyclonal antibodies against Bax, Mcl-1 (S-19), KIT (c-19), phospho-KIT on Y568/570, were from Santa Cruz Biotechnology (Santa Cruz, CA, US); antibodies against poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), p27Kip1 and p53, Becton-Dickson Biosciences Pharmingen (San Jose, CA, US); antibodies against phospho-Erk1/2 (T202/ Y204), Erk1/2, Akt, JNK, and XIAP were from Cell Signaling Technology (Beverly, MA, US); mouse monoclonal antibody specific against phosphotyrosine 705 of Stat3 (clone 9E12) and rabbit polyclonal anti-Stat3, Upstate Technology (Lake Placid, NY, US); mouse anti-human-KIT (CD117) monoclonal antibody, R&D Systems (Minneapolis, MN, US); mouse monoclonal antibody against actin, Sigma-Aldrich (Shanghai, China); rabbit anti-human RNA polymerase II, phospho-RNA polymerase II (S5), Bethyl Laboratories (Montgomery, TX, US); and anti-mouse IgG and anti-rabbit IgG horseradish peroxidase-conjugated antibodies, Pierce Biotechnology (Rockford, IL, US).

Techniques: Expressing, Control

Journal: Journal of immunotoxicology

Article Title: The early growth response factor-1 contributes to interleukin-13 production by mast cells in response to stem cell factor stimulation.

doi: 10.1080/15476910802129612

Figure Lengend Snippet: FIG. 4. Egr-1 deficiency has no effects on c-Kit and IgE receptor expression or mast-cell viability. (A) Bone marrow cells from wild-type mice or Egr-1– deficient mice were cultured in conditioned media in vitro for 4 wk and exam- ined by flow cytometry for c-Kit and IgE receptor expression. For c-Kit anal- ysis, BMMCs were stained with FITC conjugated rat anti-mouse c-Kit mAb or FITC conjugated rat IgG2a isotypic control. For analysis of IgE receptor expression, BMMC were sensitized with IgE overnight and then stained with FITC-conjugated anti-IgE antibody (mouse IgG1). No difference in c-Kit or IgE receptor expression was observed between Egr-1+/+ and Egr-1−/−BMMCs. (B) BMMC from Egr-1-deficient mice or wild-type mice cultured in complete media containing WEHI-3B supernatants (a source of IL-3) were healthy and showed ≥96% viability. To induce mast cell death, WEHI-3B supernatant was removed from culture media for various days. Mast cell viability was examined by trypan blue exclusion assay. Data were expressed as mean ± SD (n = 3 independent experiments).

Article Snippet: Fluorescein isothiocyanate (FITC) anti-mouse CD117 monoclonal antibody (mAb) (CL8936F), FITC rat IgG2a (CLCR2A01) were purchased from Cedarlane Laboratories Limited (Ontario, Canada).

Techniques: Expressing, Cell Culture, In Vitro, Cytometry, Staining, Control, Trypan Blue Exclusion Assay